AstraZeneca Gives Iressa Another Go In The EU
This article was originally published in The Pink Sheet Daily
Executive Summary
Filing for marketing authorization in lung cancer comes three years after AstraZeneca initially withdrew its application.
You may also be interested in...
AstraZeneca Executive VP, Discovery Research, Jan Lundberg, An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Exec addresses oncology pipeline, Bristol diabetes deal.
AstraZeneca Could Seek New Indication For Iressa In Europe
The company announces withdrawal of European Marketing Authorisation Application for gefitinib in treatment of non-small cell lung cancer. FDA is expected to provide an update on the status of Iressa's subpart H approval in January or February.
Iressa Promotion Halted; AstraZeneca To Highlight Tarceva Survival Benefit
Gefitinib fails to demonstrate a survival benefit in the Iressa Survival Evaluation in Lung cancer confirmatory trial. AstraZeneca will meet with FDA to determine whether accelerated approval licensure of Iressa will be withdrawn, CEO McKillop says.